Study of the Fecal Microbiome in Patients With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

October 9, 2022

Study Completion Date

October 12, 2022

Conditions
Parkinson Disease
Interventions
DRUG

PRIM-DJ2727

Twice filtered fecal microbiota product from three screened healthy donors will be lyophilized and encapsulated in enteric-coated capsules. Each dose of enteric coated capsules consists of 60 grams of stool and will be administered orally twice-weekly for 12 consecutive weeks

DRUG

Placebo oral capsule

Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria. The placebo will consist of Lactose (spray-dried United States Pharmacopeia (USP) 64.385gm), food color, powdered Black, Brown, and Yellow in the enteric capsules. Placebo will be administered orally twice-weekly for 12 consecutive weeks

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

Sponsors
All Listed Sponsors
collaborator

Kelsey Research Foundation

OTHER

lead

The University of Texas Health Science Center, Houston

OTHER